Expert Insights
Precision Therapy for Advanced Cholangiocarcinoma: Focus on FGFR Inhibitors
Release Date: May 25, 2022
Expiration Date: May 24, 2023
CE/CME Credit Hours: 1.00
Pharmacology Credit Hours: 1.00
Begin »
Program Overview
Program Description
Cholangiocarcinoma (CCA) is a relatively rare form of cancer. It encompasses a heterogenous group of malignancies that can emerge from different anatomic sites along the biliary tree. To date, surgical resection has been the only approach that offers a chance of cure; however, only a limited proportion of patients are surgical candidates because the majority are diagnosed when the disease is advanced and considered to be unresectable. Presently, systemic chemotherapy with gemcitabine in combination with a platinum agent is the established frontline treatment for patients with unresectable locally advanced or metastatic CCA. Efforts to characterize the genetic abnormalities occurring in CCA have paid off and opened up opportunities to target the identified genetic alterations, including FGFR fusions/alterations, IDH1 mutations, BRAF mutations, and NTRK fusions. Therefore, the addition of effective targeted therapies into the treatment armamentarium is anticipated to broaden and improve the survival rate for patients harboring these genetic alterations. At present, 2 FGFR inhibitors, pemigatinib and infigratinib, are approved for use in previously treated unresectable locally advanced or metastatic CCA with FGFR2 fusion/rearrangement, and there are several ongoing trials investigating these agents as well as other FGFR inhibitors in various disease settings. In this activity, Philip A. Philip, MD, PhD, FRCP discusses the role of FGFR alterations in CCA and the recommended use of FGFR inhibitors in clinical practice, as well as strategies for recognizing, monitoring, and managing the classic adverse events (AEs) associated with these agents, promoting treatment adherence and educating patients.
Format
eNewsletter with interactive benchmarking and audio commentary
Learning Objectives
After completing this activity, participants should be better able to:
- Identify recommended biomarkers and tests to guide therapy for advanced CCA
- Assess data from clinical trials and evidence-based guidelines to identify treatments for patients with FGFR2-rearranged CCA
- Apply strategies to recognize and manage AEs of novel therapies for CCA
Target Audience
Oncology NPs, PAs, and nurses
Faculty
Philip A. Philip, MD, PhD, FRCP
- Professor
- School of Medicine
- Wayne State University
- Leader
- Gastrointestinal Multidisciplinary Team
- Department of Oncology
- Henry Ford Cancer Institute
- Detroit, Michigan
Details
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP Course Advisor: Kristen O'Hagan, MSN, ANP-BC, AOCNP, Memorial Sloan Kettering Cancer Center, Montvale, New Jersey
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until May 24, 2023. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California.
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity is supported by an educational grant from Incyte Corporation.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Philip A. Philip, MD, PhD, FRCP: consultant/advisor/speaker: Astellas, AstraZeneca, Bayer, Blueprint, Daiichi Sankyo, Erytech, Genentech, Incyte, Ipsen, Merck, Novartis, Novocure, Rafael, Seagen, TriSalus; research support: Astellas, BeiGene, Incyte, NGM Bio, Karyopharm, Novocure, QED, Rafael, Syncore, Thyme.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Review the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of 67%.
The estimated time to complete this activity is 1.00 hour.
Release date: May 25, 2022
Expiration date: May 24, 2023
For Practicing Clinicians Exchange general information, contact pce@practicingclinicians.com.
© 2022 Practicing Clinicians Exchange. All Rights Reserved. PRP4628